Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- REBOOT-PARADOX: TAVR vs. OMT in Symptomatic Patients With pLFLGDespite premature termination limiting the precision of mortality estimates, the REBOOT-PARADOX trial offers rare randomized, long-term patient-level data examining whether TAVR adds a survival benefit compared with optimal medical therapy (OMT) in symptomatic patients with paradoxical low-flow, low-gradient aortic stenosis (pLFLG).
- ViVA: Vericiguat For the Treatment of Coronary VasospasmVericiguat did not improve peripheral vasodilator function or anginal symptoms in patients with angina and no obstructive coronary arteries (ANOCA) and with epicardial and/or microvascular vasospasm.
- CMR GUIDE: ICD vs. ILR in Reducing Sudden Cardiac Death and HSVAImplantation of an ICD did not significantly reduce sudden cardiac death (SCD) or hemodynamically significant ventricular arrhythmia (HSVA) compared with an implantable loop recorder (ILR) in patients with an LVEF of 36% to 50% and myocardial scar, based on results from the CMR GUIDE trial...
- ACACIA-HCM: Aficamten vs. Placebo in Treating Symptomatic Non-Obstructive HCMPatients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM) who were treated with aficamten vs. placebo saw significantly greater improvement in exercise capacity and self-reported health status at 36 weeks, according to findings from the ACACIA-HCM trial...
- POET-II: Tailored Antibiotic Strategy vs. Standard Therapy For Treating Left-Sided Infective CarditisIn patients with left-sided infective endocarditis a clinical response-tailored antibiotic strategy shortened antibiotic duration by two weeks compared with standard therapy, with no major safety concerns, based on findings from the POET-II study...